Diamyd Medical provides general update ahead of today’s Annual General Meeting

At today's Annual General Meeting, CEO Ulf Hannelius will present the latest updates with the precision medicine and antigen-specific immunotherapy Diamyd[®] as well as ongoing and upcoming developments at the Company’s manufacturing facility in Umeå in the north of Sweden. The meeting will be held at 3:00 pm CET in Stockholm.Phase III trial is recruiting patients in Europe and is approved by FDA to start in the USThe confirmatory Phase III trial DIAGNODE-3, evaluating the safety and efficacy of the antigen-specific immunotherapy Diamyd[®] in individuals diagnosed with type 1 diabetes is